Health
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19 – GlobeNewswire
Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) and QIMR Berghofer Medical Research Institute (QIMR Berghofer), one of Australias most successful medical research institutes, announced today the publishing of a new article providing evidence of apabetalones potential benefit on SARS-CoV-2 (COVID-19). The article, titled: Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical),…
-
General21 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News17 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Noosa News24 hours agoTips to improve engagement – Proctor